Navigation Links
EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
Date:8/7/2009

HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research and Development.

Dr. Fewell possesses more than 10 years management and scientific leadership experience in the biotechnology industry and has served at EGEN since 2003 as Director of Biology and Pharmacology. During his tenure at EGEN he has helped lead the development and testing of proprietary discovery and development initiatives contributing to a strong intellectual property position. He has been instrumental in building EGEN's research and development team and has helped foster important industry collaborations. Dr. Fewell received his Ph.D. in Biological Science from Florida State University and was a post-doctoral fellow at Cincinnati's Children Hospital. During his active career in research and development, Dr. Fewell has authored numerous scientific publications and is a named inventor on several patents and patent applications in the area of non-viral gene and siRNA delivery.

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit http://www.egeninc.com/ .


'/>"/>
SOURCE EGEN, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
2. AOBO Announces New Product Launch
3. Prix Galien USA Announces 2009 Final Candidates
4. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
5. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
6. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
7. Telik Announces Second Quarter 2009 Financial Results
8. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
9. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
10. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
11. Oncothyreon announces webcast of second quarter 2009 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion ... VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical ...
(Date:1/12/2017)... AURORA, Colo (PRWEB) , ... January 12, 2017 ... ... and then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a ... eLife describes a new drug combination that has stabilized Rosendahl’s disease and increased ...
(Date:1/12/2017)... The report "Direct-Fed Microbials Market by Type (Lactic Acid Bacteria and Bacillus), Livestock (Pork/Swine, Poultry, ... to 2022", published by MarketsandMarkets, the global market is estimated to be valued ... by 2022, at a CAGR of 6.96% from 2016. ... ... ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... clinics in Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand ... path of discovery. , Now, as an assistant professor of biology and biotechnology ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... Advancements in biometrics will radically ... wellbeing (HWW), and security of vehicles by ... vehicles begin to feature fingerprint recognition, iris ... monitoring, brain wave monitoring, stress detection, fatigue ... detection. These will be driven by built-in, ...
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
Breaking Biology News(10 mins):